Journal Name:
- Advance Research in Pharmaceuticals and Biologicals
| Author Name |
|---|
Abstract (2. Language):
Diabetes is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion,
insulin action, or both. The chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction,and
failure of different organs, especially the eyes, kidneys, nerves, heart, and blood vessel. Diet remains the mainstay of
treatment. If diet alone is unsuccessful then, for most patients, short-acting sulphonylurea agents are the treatment of
choice. Second line agents include the biguanide, or an α-glucosidase inhibitor. As Diabetes mellitus is concerned with
other complications so combined therapy is beneficial as Combination therapy has various advantages over
monotherapy. voglibose is an alpha-glucosidase inhibitor which reduces intestinal absorption of starch, dextrin, and
disaccharides by inhibiting the action of á-glucosidase in the intestinal brush border. Metformin lowers both basal and
postprandial blood glucose. Metformin decreases hepatic glucose production, decrease intestinal absorption of glucose
and improves peripheral glucose uptake and utilization. Metformin is the first-line drug of choice for the treatment of
type 2 diabetes, particularly in overweight and obese people and those with normal kidney function. Bi-layered tablets
increases patient compliance and also allows for designing and modulating the dissolution and release characteristics
and they are prepared with one layer of drug for immediate release while second layer designed to release drug latter in
sustained release manner.
Bookmark/Search this post with
FULL TEXT (PDF):
- 2
289-294